Dengue Fever Surges by 400% in Brazil after Bill Gates-Backed Gene-Edited Mosquitos Released
HEALTH, 4 Mar 2024
Jamie White | Infowars - TRANSCEND Media Service
Money and Weaponized Mosquitos: The dramatic spike in dengue cases has prompted Brazil to purchase millions of doses of the dengue vaccine.
- The UN’s World Mosquito Program last year announced plan to release billions of gene-edited mosquitos in Brazil.
- That mosquito program was partially funded by the Bill & Melinda Gates Foundation.
26 Feb 2024 – Dengue fever has spiked fourfold in Brazil in 2024 following the release of millions of gene-edited mosquitos by the United Nations’ World Mosquito Program.
In the first five weeks of 2024, over 364,000 cases of dengue infection have been reported, according to the country’s health ministry, which is 4x greater than previous cases in the same period of 2023.
The dramatic spike in dengue cases has prompted Brazil to purchase millions of doses of the dengue vaccine.
From The Guardian:
The rapid spread of dengue has caused 40 confirmed deaths, the ministry said, and a further 265 are being investigated.
Brazil has bought 5.2m doses of the dengue vaccine Qdenga, developed by Japanese drugmaker Takeda, with another 1.32m doses provided at no cost to the government, a ministry statement said.
Three Brazilian states have declared emergencies, including the second most populous state, Minas Gerais, and the Federal District, where the capital, Brasília, is located and is facing an unprecedented rise in infections.
Brasília will start vaccinating children aged 10-14 on Friday with Qdenga, the local government said on Wednesday.
Cases of dengue in Brasília since the start of the year have exceeded the total for the whole of 2023, with a rate of infection of 1,625 cases per 100,000 inhabitants, compared with the national average of just 170.
The UN’s World Mosquito Program announced in 2023 a plan to release billions of gene-edited mosquitos in Brazil over a 10-year period in a bid to eradicate dengue fever in the country.
“Brazilian health officials in five cities have been releasing clouds of lab-grown Aedes aegypti mosquitoes infected with Wolbachia bacteria, which prevents dengue virus transmission to humans,” Harvard Public Health reported in August 2023.
“The country will be the first to launch a nationwide program to release Wolbachia-modified mosquitoes, which are expected to protect up to 70 million people from dengue fever over the next 10 years. And it’s building a factory to scale up mosquito production: Beginning 2024, the factory will mass-produce five billion mosquitoes a year.”
Now a year after the mosquito initiative began, dengue cases have risen sharply rather than fallen.
Notably, the World Mosquito Program received a $50 million grant from the Bill & Melinda Gates Foundation.
The Bill & Melinda Gates Foundation is also bankrolling research into the dengue fever vaccine.
The Brazilian government purchased over 5 million doses of the Qdenga dengue fever vaccine, manufactured by Japanese drugmaker Takeda, which also received millions of dollars in grants from the Bill & Melinda Gates Foundation.
In other words, Bill Gates Foundation money is involved in all sides of the situation, from the gene-edited mosquitos — which has apparently exacerbated the dengue crisis — to bankrolling companies who are providing the in-demand dengue fever vaccine to Brazil.
To what end?
Tags: Bill Gates, Brazil, Dengue, GMO, Public Health, Vaccines
DISCLAIMER: The statements, views and opinions expressed in pieces republished here are solely those of the authors and do not necessarily represent those of TMS. In accordance with title 17 U.S.C. section 107, this material is distributed without profit to those who have expressed a prior interest in receiving the included information for research and educational purposes. TMS has no affiliation whatsoever with the originator of this article nor is TMS endorsed or sponsored by the originator. “GO TO ORIGINAL” links are provided as a convenience to our readers and allow for verification of authenticity. However, as originating pages are often updated by their originating host sites, the versions posted may not match the versions our readers view when clicking the “GO TO ORIGINAL” links. This site contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available in our efforts to advance understanding of environmental, political, human rights, economic, democracy, scientific, and social justice issues, etc. We believe this constitutes a ‘fair use’ of any such copyrighted material as provided for in section 107 of the US Copyright Law. In accordance with Title 17 U.S.C. Section 107, the material on this site is distributed without profit to those who have expressed a prior interest in receiving the included information for research and educational purposes. For more information go to: http://www.law.cornell.edu/uscode/17/107.shtml. If you wish to use copyrighted material from this site for purposes of your own that go beyond ‘fair use’, you must obtain permission from the copyright owner.
Join the discussion!
We welcome debate and dissent, but personal — ad hominem — attacks (on authors, other users or any individual), abuse and defamatory language will not be tolerated. Nor will we tolerate attempts to deliberately disrupt discussions. We aim to maintain an inviting space to focus on intelligent interactions and debates.